Литература:

1. Martin G.S., Mannino D.M., Eaton S., Moss M. The Epidemiology of Sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003;348:1546-54.

2. Jevons, M.P. ‘Celbenin’-resistant staphylococci. Br. Med. J. 1961, 1, 124-125.

3. Ito, T. et al. Cloning and nucleotide sequence determination of the entire mecDNA of pre-methicillin-resistant Staphylococcus aureus strain N315. Antimicrob. Agents Chemother. 1999, 43, 1449-1458.

4. Hiramatsu K., Cui L., Kuroda M., Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. Vol.9 No.10 2001, 9, 486 - 493.

5. Wu, S. et al. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb. Drug Res. 1996, 2, 435-441.

6. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of Mortality Associated with Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Meta-analysis. Clin. Infect. Dis. 2003; 36:53-9.

7. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, Issued August 2001. Am. J. Infect. Control. 2001:29; 404-21

8. Сидоренко С.В. Резван С.П., Грудинина С.А., Кротова Л.А., Стерхова Г.В.. Результаты многоцентрового исследования чувствительности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиотики и химиотерапия. Т43, N.7, 15-25, 1998

9. Дехнич А.В., Эдельштейн И.А., Нарезкина А.Д., и соавт. Эпидемиология антибиотикорезистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследования. Клиническая микробиология и антимикробная химиотерапия. 2002, 4, 325-336.

10. Hiramatsu K. et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997, 350, 1668-1671.

11. Hiramatsu K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997. 40, 135-136.

12. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 1992;93:195—8.

13. CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002. MMWR 2002;51:565 - 567.

14. CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002. MMWR 2002;51:902-903.

15. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997;41: 2132-2136.

16. Shinabarger D: Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Invest Drugs 1999, 8:1195-1202.

17. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.

18. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45

19. Von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinpristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43:569-73

20. Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against staphylococci and enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother 2000 Apr; 44: 1062-6

21. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001; 47: 77-81

22. Edlund C, Oh H, Nord CE. In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin Microbiol Infect 1999; 5: 51-3

23. Baum SE, Crawford SA, McElmeel ML, Whitney CG, Jorgensen JH. Comparative Activities of the Oxazolidinone AZD2563 and Linezolid against Selected Recent North American Isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 2002; 46: 3094-5.

24. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJC. In Vitro Activities of Ramoplanin, Teicoplanin, Vancomycin, Linezolid, Bacitracin, and Four Other Antimicrobials against Intestinal Anaerobic Bacteria. Antimicrobial Agents and Chemotherapy 2003; 47: 2334-8.

25. Gales AC, Sader HH, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44: 301-11.

26. Bell JM, Turnidge JD, Ballow CH, Jones RN, the ZAPS RP. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. Journal of Antimicrobial Chemotherapy 2003; 51: 339-45.

27. Miyazaki S, Fujikawa T, Kobayashi I, Matsumoto T, Tateda K, Yamaguchi K. The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and -resistant enterococci. Journal of Antimicrobial Chemotherapy 2002; 50: 971-4.

28. John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. Journal of Antimicrobial Chemotherapy 2002; 50: 933-8.

29. Wootton M, Howe RA, Walsh TR, Bennett PM, MacGowan AP. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). Journal of Antimicrobial Chemotherapy 2002; 50: 760-1.

30. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40:839-845.

31. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, Dailey CF, Ford CW, Batts DH, Gibson JK: Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 2001, 47:349-352.

32. Gemmell C, Ford C: Expression of virulence factors by Grampositive cocci exposed to sub-MIC levels of linezolid. Abstract 1537 of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999 September 26-29, San Francisco.

33. Coyle EA, Cha R, Rybak MJ. Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release. Antimicrobial Agents and Chemotherapy 2003; 47: 1752.

34. Pharmacia and Upjohn Company. Kalamazoo M USA. Linezolid prescribing information. Available from: http://www.zyvox.com/fullprescribe.htm

35. Olsen K, Preheim L, Gentry-Nielsen M: The pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Abstract 2251 of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000 September 17-20, Toronto.

36. Andes D, van Ogtrop ML, Peng J, Craig WA. In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid). Antimicrobial Agents and Chemotherapy 2002; 46: 3484-9.

37. Burkhardt O, Borner K, der Hoh N et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. Journal of Antimicrobial Chemotherapy 2002; 50: 707-12.

38. Buchanan LV, Dailey CF, LeMay RJ, Zielinski RJ, Kuo MS, Gibson JK. Time-dependent antibacterial effects of linezolid in experimental rabbit endocarditis. Journal of Antimicrobial Chemotherapy 2002; 50: 440-2.

39. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. Journal of Antimicrobial Chemotherapy 2003; 51: 1239.

40. Rubinstein E, Isturiz R, Standiford HC et al. Worldwide Assessment of Linezolid’s Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies. Antimicrobial Agents and Chemotherapy 2003; 47: 1824.

41. Leach TS, Kaja RW, Eckert SM, et al. Linezolid versus vancomycin for the treatment of MRSA infections: results of a randomized phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000; Apr 10-13: Buenos Aires, 224

42. Pharmacia and Upjohn Company. Linezolid for the treatment of methicillin-resistant Staphylococcus species (MRSS) infections: a randomized, open-label trial comparing linezolid IV/PO and vancomycin. (Data on file Kalamazoo, MI, 1999)

43. Hartman CS, Leach TS, Kaja RW, et al. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20: Toronto, 488

44. Pharmacia and Upjohn Company. Linezolid for the treatment of vancomycin-resistant enterococcal infections: a double-blind trial comparing 600 mg linezolid every 12 hours with 200 mg linezolid every 12 hours. (Data on file Kalamazoo,MI, 1999)

45.Duvall SE, Sseas C, Bruss JB, et al. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000 Apr 10-13: Buenos Aires, 181

46. Mangano R, Zotti G, Voros D, et al. Comparison of linezolid and flucloxacillin in the treatment of complicated skin infections: analysis of European and South African patients in a regional phase III trial [posterA]. Third International Meeting on the Therapy of Infections; 2000 Dec 4: Florence

47.Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44 (12): 3408-13

48. Cammarata SK, Bermudez M, Golin V, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia [abstract]. 9th International Congress on Infectious Diseases; 2000; Apr 10-13: Buenos Aires, 182

49. Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [poster no. 237]. Stocklolm: ECCMID, 2000: May 28

50. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [abstract]. Am J of Resp and Crit CareMed 2000; 161 (Pt 2) Suppl.: A654

51. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [poster no. E-73]. Toronto: American Thoracic Society, 2000: May 5

52. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2000; 32: 402-12

53. Cammarata SK, Timm JA, Hempsall KA, et al. Linezolid is equivalent to vancomycin in the treatment of patients with Gram positive nosocomial pneumonia [poster no. I-135]. Toronto: American Thoracic Society, 2000: May 5

54. Сидоренко С.В. Стерхова Г.В. Грудинина С.А. и соавт. Линезолид при нозокомиальных пневмониях: результаты многоцентрового двойного слепого исследования в сравнении с ванкомицином. Антибиотики и химиотерапия. Т.47, N, 1; 12-17, 2002

55. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002 Jun 1;34(11):1481-90. 2002; 34: 1481-90.

56. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy 2002; 46: 2723-6.

57. Till M., Wixson R.L., Pertel1P.E. Linezolid Treatment for Osteomyelitis Due to Vancomycin-Resistant Enterococcus faecium . Clin.Infect Dis 2002, 34, 1412-1414 2002.